Multidrug-resistant tuberculosis among previously treated patients in the Philippines

被引:16
作者
Gler, M. T. [1 ]
Macalintal, L. E. [1 ]
Raymond, L. [1 ]
Guilatco, R. [1 ]
Quelapio, M. I. D. [1 ]
Tupasi, T. E. [1 ]
机构
[1] Trop Dis Fdn, Makati Med Ctr, Makati 1229, Metro Manila, Philippines
关键词
MDR-TB; high-burden country; Category; 1; failures; previously treated; SHORT-COURSE CHEMOTHERAPY; DRUG-RESISTANCE; TREATMENT FAILURE; RETREATMENT; PREVALENCE; CATEGORY;
D O I
10.5588/ijtld.10.0400
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
SETTING: Prior treatment has been associated with multidrug-resistant tuberculosis (MDR-TB) in many settings. The Philippines ranks fifth among 27 priority countries for MDR-TB. OBJECTIVE: To determine the rate of MDR-TB among previously treated patients referred for MDR screening and management. DESIGN: Descriptive study of the rate of MDR-TB among 4705 previously treated patients screened from 2003 to 2008. RESULTS: MDR-TB was present in 76% of 2438 screened patients who had positive cultures. The proportion of patients with MDR-TB was the same among patients referred from public or DOTS facilities and private or non-DOTS facilities. MDR-TB occurred most frequently among patients who failed treatment with the Category 2 regimen (97%), those who did not demonstrate culture conversion after 3 months of Category 2 treatment (91%), and Category 1 failures (83%). MDR-TB rates were respectively 78% and 57% for Category 2 relapse and return after default (RAD), and respectively 33% and 22% for Category 1 relapse and RAD. CONCLUSION: MDR-TB is frequent among previously treated patients in the Philippines. Screening with culture and drug susceptibility testing should be considered for these patients.
引用
收藏
页码:652 / 656
页数:5
相关论文
共 21 条
  • [1] [Anonymous], 2008, WHO/HTM/TB/2008.394
  • [2] [Anonymous], 2007, WHO REP 2007 GLOB TU
  • [3] [Anonymous], 2010, WHO/HTM/TB/2010.3
  • [4] AUER C, 2005, INT J TUBERC LUNG S1, V9, pS306
  • [5] Becerra MC, 2000, INT J TUBERC LUNG D, V4, P108
  • [6] Caminero JA, 2010, INT J TUBERC LUNG D, V14, P382
  • [7] CAMINERO JA, 2004, TB GUIDE SPECIALIST
  • [8] Chiang CY, 2010, INT J TUBERC LUNG D, V14, P672
  • [9] *DEP HLTH PHIL, 2008, GUID IMPL PROGR MAN
  • [10] Heldal E, 2001, INT J TUBERC LUNG D, V5, P129